Bioiberica leads a study to predict the evolution of arthritis from a saliva sample

Congress World of ARTHROSIS (OARSI)

-Francisco j. Blanco Garcia, rheumatologist complex Hospitalario Universitario A Coruña, introduced the draft Arthrosischip ”, to predict the evolution of arthrosis

-Bioiberica is the only Spanish pharmaceutical that participates in the 2011 OARSItwo symposia on the treatment of chronic arthritis and personalized medicine

-Barcelona will host the 2012 OARSI, with the collaboration of Bioiberica

Barcelona, 2011-September know how will evolve the osteoarthritis of knee with a simple saliva test could be a reality in the future. Thus present it Bioiberica in the world osteoarthritis Congress (OARSI) to be held in San Diego, California on 15-18 September.

Dr. Francisco j. Blanco, complex Hospitalario Universitario A Coruña rheumatologist, will be in charge of presenting the Arthrosischip ” during the Symposium of medicine custom ” organized by Bioiberica. This innovative research project seeks to develop a gene chip that can predict the progression of osteoarthritis of the knee in patients diagnosed with this disease. Based on the technology of DNA microarrays, Arthrosischip shall consist of a genetic analysis from a saliva sample. It will identify genetic mutations associated with the evolution of arthritis and clinical data, basically, risk factors such as sex or concomitant diseases of arthritis such as diabetes. It is a study jointly developed between Bioiberica, company with more than 30 years of experience in health of joints and leader in chondroprotection, and Progenika, specialist in the design and development of tools for personalized medicine.

Part of the project Arthrosischip ”, Dr. Allen Sawitzke of the Faculty of Medicine of the University of Utah, United States, will present the second phase of the project that aims to identified using biological markers and on the basis of a preliminary analysis of genetic inheritance, those patients with osteoarthritis more susceptible to rapid progress in his illness, and therefore to end up in implementation of prosthesis. This study is carried out in collaboration between Bioiberica, the University of Utah and the National Institute of Health (NIH).

Dr. Thomas Pap, University Hospital of Münster, Germany, will close the Symposium with a review of the biomarkers in osteoarthritis and its usefulness in the diagnosis, prognosis, description of the severity of the disease and analysis of the effectiveness of an intervention. The objective of this symposium is to demonstrate how personalized medicine can offer a wide range of possibilities to the patient with arthrosis, incapacitated from chronic, and often dealt with only in certain episodes of the disease. Personalized medicine can help both in its prevention and control of the progression once appeared pathology.

Effectiveness of chondroitin sulfate on osteoarthritis how arthritis has gone from being exclusively a pathology of cartilage to a pathology of the entire joint ” will be the premise that opens another Symposium Bioiberica has organized and which bears the name in osteoarthritis symptom Control: evidence with drugs for symptomatic slow action ”. One of the speakers will be Professor Jean-Pierre Pelletier, Director of the research unit in arthrosis of the Université de Montréal (Canada) and principal investigator of a recent clinical trial conducted with chondroitin sulfate in patients with osteoarthritis of the knee and evaluated by nuclear magnetic resonance. Prof. Pelletier will carry out a review of various clinical trials and meta-analysis published with chondroitin sulfate in order to assess their efficacy and safety for the treatment of osteoarthritis of the knee. These studies allow to conclude that chondroitin sulfate is a symptomatic slow action drug effective in the treatment of arthritis with an excellent safety profile. The condroprotectores, and in particular the chondroitin sulfate, are drugs that act directly on the three joint structures affected by osteoarthritis: joint cartilage, synovial membrane, and the subcondral bone. They not only relieve the symptoms of osteoarthritis, but it is proving have ability to attack the root disease, slowing down the degenerative process that takes place in the joints, primarily of hands, hips, knees, etc.

The OARSI in Barcelona in April 2012 with Bioiberica as main sponsor, the next edition of OARSI be held in Barcelona in April. During these days will gather in the city more than one thousand of specialists from around the world, including rheumatologists, researchers, orthopaedic surgeons, radiologists, clinical and other stakeholders in the research of arthritis. However, this Congress has the most prestigious professionals dedicated to the treatment of arthritis to share progress and experiences in the investigation of this disease.

Bioiberica Farma

Bioiberica Farma is the only Spanish laboratory specializing in research and development of effective drugs for the treatment of osteoarthritis. Specifically, specialises in chondroprotection, namely, prevention, diagnosis and treatment of cartilage, synovial membrane, and the subcondral bone injuries.

This expertise in the treatment of osteoarthritis has helped Bioiberica Farma occupies a leading position endorsed by numerous published clinical trials, research projects underway, the recognition of different societies scientific and medical, strict quality control chemical and biological production processes, the quality of their products and editing of publications specialised in chondroprotection.